Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H13FN5O7P |
Molecular Weight | 365.2117 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC(F)=NC2=C1N=CN2[C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]3O
InChI
InChIKey=GIUYCYHIANZCFB-FJFJXFQQSA-N
InChI=1S/C10H13FN5O7P/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(18)5(17)3(23-9)1-22-24(19,20)21/h2-3,5-6,9,17-18H,1H2,(H2,12,14,15)(H2,19,20,21)/t3-,5-,6+,9-/m1/s1
Molecular Formula | C10H13FN5O7P |
Molecular Weight | 365.2117 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Fludarabine or fludarabine phosphate is a chemotherapy drug used in the treatment of hematological malignancies (cancers of blood cells such as leukemias and lymphomas). It is a purine analog, which interferes with DNA synthesis. Fludarabine phosphate is a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-β-D-arabinofuranosyladenine (ara-A), that is relatively resistant to deamination by adenosine deaminase. Fludarabine (marketed as fludarabine phosphate under the trade name Fludara) is a chemotherapy drug used in the treatment of hematological malignancies. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis. The mechanism of action of this antimetabolite is not completely characterized and may be multi-faceted.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1828 |
|||
Target ID: CHEMBL1830 Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=23115527 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | FLUDARABINE PHOSPHATE Approved UseFludarabine Phosphate Injection is indicated for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL)
who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. The safety and effectiveness of Fludarabine Phosphate Injection in previously untreated or non-refractory patients with CLL have not been established. Important Limitations Fludarabine Phosphate Injection should not be used in patients with severe renal impairment (creatinine clearance less than 30 mL/min/1.73 m2). Launch Date1.19024635E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.28 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17211431 |
30 mg/m² single, intravenous dose: 30 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
FLUDARABINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
21.55 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17211431 |
30 mg/m² single, intravenous dose: 30 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
FLUDARABINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.9 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17211431 |
30 mg/m² single, intravenous dose: 30 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
FLUDARABINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
20 h |
25 mg/m² 1 times / day multiple, intravenous dose: 25 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: |
FLUDARABINE plasma | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
100 mg/m2 1 times / day multiple, intravenous Highest studied dose Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: |
unhealthy, 32 years (range: 19-59 years) n = 2 Health Status: unhealthy Condition: Acute Leukemia Age Group: 32 years (range: 19-59 years) Sex: M+F Population Size: 2 Sources: |
Other AEs: Leukopenia... |
40 mg/m2 1 times / day steady, intravenous MTD Dose: 40 mg/m2, 1 times / day Route: intravenous Route: steady Dose: 40 mg/m2, 1 times / day Sources: |
unhealthy, 32 years (range: 19-59 years) n = 11 Health Status: unhealthy Condition: Acute Leukemia Age Group: 32 years (range: 19-59 years) Sex: M+F Population Size: 11 Sources: |
|
20 mg/m2 1 times / day multiple, intravenous MTD Dose: 20 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 20 mg/m2, 1 times / day Sources: |
unhealthy, 55 years (range: 26-78 years) Health Status: unhealthy Age Group: 55 years (range: 26-78 years) Sex: M+F Sources: |
|
45 mg/m2 1 times / day multiple, intravenous Dose: 45 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 45 mg/m2, 1 times / day Sources: |
unhealthy, 55 years (range: 26-78 years) n = 1 Health Status: unhealthy Age Group: 55 years (range: 26-78 years) Sex: M+F Population Size: 1 Sources: |
DLT: Myelosuppression... Dose limiting toxicities: Myelosuppression (1 patient) Sources: |
40 mg/m2 1 times / day steady, oral Recommended Dose: 40 mg/m2, 1 times / day Route: oral Route: steady Dose: 40 mg/m2, 1 times / day Sources: Page: p. 61 |
unhealthy, 64 years (range: 30-75 years) n = 81 Health Status: unhealthy Age Group: 64 years (range: 30-75 years) Sex: M+F Population Size: 81 Sources: Page: p. 61 |
Disc. AE: Thrombocytopenia, Anemia hemolytic autoimmune... AEs leading to discontinuation/dose reduction: Thrombocytopenia (1 patient) Sources: Page: p. 61Anemia hemolytic autoimmune (3 patients) Pneumonia (1 patient) Anemia (1 patient) Foot drop (1 patient) Sepsis (1 patient) Bronchitis (1 patient) Rash (1 patient) Face edema (1 patient) |
25 mg/m2 1 times / day steady, intravenous Recommended Dose: 25 mg/m2, 1 times / day Route: intravenous Route: steady Dose: 25 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: B-cell chronic lymphocytic leukemia Age Group: adult Sources: |
Other AEs: CNS toxicity, Hemolytic anemia... Other AEs: CNS toxicity Sources: Hemolytic anemia Pulmonary toxicity |
40 mg/m2 1 times / day steady, oral Recommended Dose: 40 mg/m2, 1 times / day Route: oral Route: steady Dose: 40 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: B-cell chronic lymphocytic leukemia Age Group: adult Sources: |
Other AEs: CNS toxicity, Hemolytic anemia... Other AEs: CNS toxicity Sources: Hemolytic anemia Pulmonary toxicity |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Leukopenia | 2 patients | 100 mg/m2 1 times / day multiple, intravenous Highest studied dose Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: |
unhealthy, 32 years (range: 19-59 years) n = 2 Health Status: unhealthy Condition: Acute Leukemia Age Group: 32 years (range: 19-59 years) Sex: M+F Population Size: 2 Sources: |
Myelosuppression | 1 patient DLT, Disc. AE |
45 mg/m2 1 times / day multiple, intravenous Dose: 45 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 45 mg/m2, 1 times / day Sources: |
unhealthy, 55 years (range: 26-78 years) n = 1 Health Status: unhealthy Age Group: 55 years (range: 26-78 years) Sex: M+F Population Size: 1 Sources: |
Anemia | 1 patient Disc. AE |
40 mg/m2 1 times / day steady, oral Recommended Dose: 40 mg/m2, 1 times / day Route: oral Route: steady Dose: 40 mg/m2, 1 times / day Sources: Page: p. 61 |
unhealthy, 64 years (range: 30-75 years) n = 81 Health Status: unhealthy Age Group: 64 years (range: 30-75 years) Sex: M+F Population Size: 81 Sources: Page: p. 61 |
Bronchitis | 1 patient Disc. AE |
40 mg/m2 1 times / day steady, oral Recommended Dose: 40 mg/m2, 1 times / day Route: oral Route: steady Dose: 40 mg/m2, 1 times / day Sources: Page: p. 61 |
unhealthy, 64 years (range: 30-75 years) n = 81 Health Status: unhealthy Age Group: 64 years (range: 30-75 years) Sex: M+F Population Size: 81 Sources: Page: p. 61 |
Face edema | 1 patient Disc. AE |
40 mg/m2 1 times / day steady, oral Recommended Dose: 40 mg/m2, 1 times / day Route: oral Route: steady Dose: 40 mg/m2, 1 times / day Sources: Page: p. 61 |
unhealthy, 64 years (range: 30-75 years) n = 81 Health Status: unhealthy Age Group: 64 years (range: 30-75 years) Sex: M+F Population Size: 81 Sources: Page: p. 61 |
Foot drop | 1 patient Disc. AE |
40 mg/m2 1 times / day steady, oral Recommended Dose: 40 mg/m2, 1 times / day Route: oral Route: steady Dose: 40 mg/m2, 1 times / day Sources: Page: p. 61 |
unhealthy, 64 years (range: 30-75 years) n = 81 Health Status: unhealthy Age Group: 64 years (range: 30-75 years) Sex: M+F Population Size: 81 Sources: Page: p. 61 |
Pneumonia | 1 patient Disc. AE |
40 mg/m2 1 times / day steady, oral Recommended Dose: 40 mg/m2, 1 times / day Route: oral Route: steady Dose: 40 mg/m2, 1 times / day Sources: Page: p. 61 |
unhealthy, 64 years (range: 30-75 years) n = 81 Health Status: unhealthy Age Group: 64 years (range: 30-75 years) Sex: M+F Population Size: 81 Sources: Page: p. 61 |
Rash | 1 patient Disc. AE |
40 mg/m2 1 times / day steady, oral Recommended Dose: 40 mg/m2, 1 times / day Route: oral Route: steady Dose: 40 mg/m2, 1 times / day Sources: Page: p. 61 |
unhealthy, 64 years (range: 30-75 years) n = 81 Health Status: unhealthy Age Group: 64 years (range: 30-75 years) Sex: M+F Population Size: 81 Sources: Page: p. 61 |
Sepsis | 1 patient Disc. AE |
40 mg/m2 1 times / day steady, oral Recommended Dose: 40 mg/m2, 1 times / day Route: oral Route: steady Dose: 40 mg/m2, 1 times / day Sources: Page: p. 61 |
unhealthy, 64 years (range: 30-75 years) n = 81 Health Status: unhealthy Age Group: 64 years (range: 30-75 years) Sex: M+F Population Size: 81 Sources: Page: p. 61 |
Thrombocytopenia | 1 patient Disc. AE |
40 mg/m2 1 times / day steady, oral Recommended Dose: 40 mg/m2, 1 times / day Route: oral Route: steady Dose: 40 mg/m2, 1 times / day Sources: Page: p. 61 |
unhealthy, 64 years (range: 30-75 years) n = 81 Health Status: unhealthy Age Group: 64 years (range: 30-75 years) Sex: M+F Population Size: 81 Sources: Page: p. 61 |
Anemia hemolytic autoimmune | 3 patients Disc. AE |
40 mg/m2 1 times / day steady, oral Recommended Dose: 40 mg/m2, 1 times / day Route: oral Route: steady Dose: 40 mg/m2, 1 times / day Sources: Page: p. 61 |
unhealthy, 64 years (range: 30-75 years) n = 81 Health Status: unhealthy Age Group: 64 years (range: 30-75 years) Sex: M+F Population Size: 81 Sources: Page: p. 61 |
CNS toxicity | 25 mg/m2 1 times / day steady, intravenous Recommended Dose: 25 mg/m2, 1 times / day Route: intravenous Route: steady Dose: 25 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: B-cell chronic lymphocytic leukemia Age Group: adult Sources: |
|
Hemolytic anemia | 25 mg/m2 1 times / day steady, intravenous Recommended Dose: 25 mg/m2, 1 times / day Route: intravenous Route: steady Dose: 25 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: B-cell chronic lymphocytic leukemia Age Group: adult Sources: |
|
Pulmonary toxicity | 25 mg/m2 1 times / day steady, intravenous Recommended Dose: 25 mg/m2, 1 times / day Route: intravenous Route: steady Dose: 25 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: B-cell chronic lymphocytic leukemia Age Group: adult Sources: |
|
CNS toxicity | 40 mg/m2 1 times / day steady, oral Recommended Dose: 40 mg/m2, 1 times / day Route: oral Route: steady Dose: 40 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: B-cell chronic lymphocytic leukemia Age Group: adult Sources: |
|
Hemolytic anemia | 40 mg/m2 1 times / day steady, oral Recommended Dose: 40 mg/m2, 1 times / day Route: oral Route: steady Dose: 40 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: B-cell chronic lymphocytic leukemia Age Group: adult Sources: |
|
Pulmonary toxicity | 40 mg/m2 1 times / day steady, oral Recommended Dose: 40 mg/m2, 1 times / day Route: oral Route: steady Dose: 40 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: B-cell chronic lymphocytic leukemia Age Group: adult Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_ClinPharmR.pdf#page=41 Page: 41.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_ClinPharmR.pdf#page=41 Page: 41.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_ClinPharmR.pdf#page=27 Page: 27.0 |
weak |
PubMed
Title | Date | PubMed |
---|---|---|
In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. | 1982 Mar |
|
Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia. | 1993 Mar |
|
Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. | 1993 Mar |
|
Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells. | 1994 Dec |
|
Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells. | 1994 Dec |
|
Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells. | 1998 Jul-Aug |
|
Fatal peripheral neuropathy following FLA chemotherapy. | 2004 Aug |
|
Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway. | 2004 Dec 16 |
|
9-beta-D-arabinofuranosyl-2-fluoroadenine inhibits expression of vascular endothelial growth factor through hypoxia-inducible factor-1 in human ovarian cancer cells. | 2004 Jul |
|
Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. | 2004 May 24 |
|
Inhibition of repair of carboplatin-induced DNA damage by 9-beta-D-arabinofuranosyl-2-fluoroadenine in quiescent human lymphocytes. | 2004 Nov 1 |
|
A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia. | 2004 Oct 15 |
|
Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. | 2005 Apr 22 |
|
Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase. | 2005 Dec |
|
Resistance to 9-beta-D-arabinofuranosyl-2-fluoroadenine due to reduced incorporation into DNA from competition by excess deoxyadenosine triphosphate: implications for different sensitivities to nucleoside analogues. | 2005 Jun |
|
A highly sensitive high-performance liquid chromatography-mass spectrometry method for quantification of fludarabine triphosphate in leukemic cells. | 2005 Jun 25 |
|
Inhibition of the PI3K pathway sensitizes fludarabine-induced apoptosis in human leukemic cells through an inactivation of MAPK-dependent pathway. | 2005 Jun 3 |
|
Alteration of DNA methylation status in K562 and MCF-7 cancer cell lines by nucleoside analogues. | 2006 |
|
Characterization of the rat Na+/nucleoside cotransporter 2 and transport of nucleoside-derived drugs using electrophysiological methods. | 2006 Dec |
|
Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma. | 2006 Feb |
|
Chronic lymphocytic leukaemia, synchronous small cell carcinoma and squamous neoplasia of the urinary bladder in a paraplegic man following long-term phenoxybenzamine therapy. | 2006 Mar |
|
MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. | 2006 May 15 |
|
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). | 2006 May 15 |
|
Role of fludarabine in hematological malignancies. | 2006 Sep |
|
[Prognostic significance of immunoglobulin variable region gene mutations in B-CLL patients treated with combination therapy fludarabine plus cyclophosphamide]. | 2007 |
|
Fatal leukoencephalopathy after reduced-intensity allogeneic stem cell transplantation. | 2007 Feb |
|
Myelopathy due to intrathecal chemotherapy: magnetic resonance imaging findings. | 2007 Feb |
|
STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines. | 2007 Jan 1 |
|
Cutaneous recall phenomenon at the site of previous doxorubicin extravasation after second-line chemotherapy. | 2007 Jan 17 |
|
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. | 2007 Jul 21 |
|
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. | 2007 Mar 20 |
|
Drug resistance in B-cell chronic lymphocytic leukemia: predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay. | 2007 May |
|
Prodrug converting enzyme gene delivery by L. monocytogenes. | 2008 Apr 10 |
|
Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. | 2008 Jan 1 |
|
Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells. | 2008 Mar |
|
Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia. | 2008 Mar 15 |
|
Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells. | 2008 May 15 |
|
Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration. | 2008 Nov |
|
Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. | 2008 Oct |
|
Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphamide/rituximab for low grade non-Hodgkin's lymphoma. | 2008 Oct 27 |
|
Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients. | 2008 Sep |
|
Fludarabine in the treatment of chronic lymphocytic leukemia: a review. | 2009 Feb |
|
ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC. | 2009 Feb 20 |
|
Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. | 2009 Jan |
|
Hypomethylation and induction of retinoic acid receptor beta 2 by concurrent action of adenosine analogues and natural compounds in breast cancer cells. | 2010 Jul 25 |
|
Use of clofarabine for acute childhood leukemia. | 2010 Jun 24 |
|
Incidence and susceptibility to therapy-related myeloid neoplasms. | 2010 Mar 19 |
|
The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. | 2011 Jan 15 |
|
Inhibitory effect of leptin on rosiglitazone-induced differentiation of primary adipocytes prepared from TallyHO/Jng mice. | 2011 Mar 25 |
|
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | 2015 May 18 |
Sample Use Guides
Chronic Lymphocytic Leukemia (CLL): The recommended adult dose is 25 mg/m2 administered intravenously over a period of approximately 30 minutes daily for five consecutive days. Each 5-day course of treatment should commence every 28 days.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21223714
The growth of RPMI8226 and KM3 cells was suppressed by fludarabine treatment in a dose and time-dependent manner. After treatment with fludarabine for 24 h, the IC(50) for RPMI8226 cells was 2.13 µg/ml, and 0.36 µg/ml for KM3 cells. Apoptotic cells of RPMI8226 and KM3 increased in a dose- dependent manner after exposure to fludarabine for 24 h. Western blot analysis showed the activation of caspase-3 and PARP in the MM cells treated with fludarabine.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:26:26 UTC 2023
by
admin
on
Fri Dec 15 15:26:26 UTC 2023
|
Record UNII |
1X9VK9O1SC
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1556
Created by
admin on Fri Dec 15 15:26:26 UTC 2023 , Edited by admin on Fri Dec 15 15:26:26 UTC 2023
|
||
|
FDA ORPHAN DRUG |
35889
Created by
admin on Fri Dec 15 15:26:26 UTC 2023 , Edited by admin on Fri Dec 15 15:26:26 UTC 2023
|
||
|
FDA ORPHAN DRUG |
250607
Created by
admin on Fri Dec 15 15:26:26 UTC 2023 , Edited by admin on Fri Dec 15 15:26:26 UTC 2023
|
||
|
FDA ORPHAN DRUG |
27688
Created by
admin on Fri Dec 15 15:26:26 UTC 2023 , Edited by admin on Fri Dec 15 15:26:26 UTC 2023
|
||
|
NCI_THESAURUS |
C2150
Created by
admin on Fri Dec 15 15:26:26 UTC 2023 , Edited by admin on Fri Dec 15 15:26:26 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB01073
Created by
admin on Fri Dec 15 15:26:26 UTC 2023 , Edited by admin on Fri Dec 15 15:26:26 UTC 2023
|
PRIMARY | |||
|
SUB13897MIG
Created by
admin on Fri Dec 15 15:26:26 UTC 2023 , Edited by admin on Fri Dec 15 15:26:26 UTC 2023
|
PRIMARY | |||
|
1X9VK9O1SC
Created by
admin on Fri Dec 15 15:26:26 UTC 2023 , Edited by admin on Fri Dec 15 15:26:26 UTC 2023
|
PRIMARY | |||
|
m5427
Created by
admin on Fri Dec 15 15:26:26 UTC 2023 , Edited by admin on Fri Dec 15 15:26:26 UTC 2023
|
PRIMARY | Merck Index | ||
|
25102
Created by
admin on Fri Dec 15 15:26:26 UTC 2023 , Edited by admin on Fri Dec 15 15:26:26 UTC 2023
|
PRIMARY | RxNorm | ||
|
75607-67-9
Created by
admin on Fri Dec 15 15:26:26 UTC 2023 , Edited by admin on Fri Dec 15 15:26:26 UTC 2023
|
PRIMARY | |||
|
C1102
Created by
admin on Fri Dec 15 15:26:26 UTC 2023 , Edited by admin on Fri Dec 15 15:26:26 UTC 2023
|
PRIMARY | |||
|
312887
Created by
admin on Fri Dec 15 15:26:26 UTC 2023 , Edited by admin on Fri Dec 15 15:26:26 UTC 2023
|
PRIMARY | |||
|
1X9VK9O1SC
Created by
admin on Fri Dec 15 15:26:26 UTC 2023 , Edited by admin on Fri Dec 15 15:26:26 UTC 2023
|
PRIMARY | |||
|
30751
Created by
admin on Fri Dec 15 15:26:26 UTC 2023 , Edited by admin on Fri Dec 15 15:26:26 UTC 2023
|
PRIMARY | |||
|
328002
Created by
admin on Fri Dec 15 15:26:26 UTC 2023 , Edited by admin on Fri Dec 15 15:26:26 UTC 2023
|
PRIMARY | |||
|
T-29
Created by
admin on Fri Dec 15 15:26:26 UTC 2023 , Edited by admin on Fri Dec 15 15:26:26 UTC 2023
|
PRIMARY | |||
|
DTXSID2023060
Created by
admin on Fri Dec 15 15:26:26 UTC 2023 , Edited by admin on Fri Dec 15 15:26:26 UTC 2023
|
PRIMARY | |||
|
100000090025
Created by
admin on Fri Dec 15 15:26:26 UTC 2023 , Edited by admin on Fri Dec 15 15:26:26 UTC 2023
|
PRIMARY | |||
|
CHEMBL1096882
Created by
admin on Fri Dec 15 15:26:26 UTC 2023 , Edited by admin on Fri Dec 15 15:26:26 UTC 2023
|
PRIMARY | |||
|
1189
Created by
admin on Fri Dec 15 15:26:26 UTC 2023 , Edited by admin on Fri Dec 15 15:26:26 UTC 2023
|
PRIMARY | |||
|
63599
Created by
admin on Fri Dec 15 15:26:26 UTC 2023 , Edited by admin on Fri Dec 15 15:26:26 UTC 2023
|
PRIMARY | |||
|
1272204
Created by
admin on Fri Dec 15 15:26:26 UTC 2023 , Edited by admin on Fri Dec 15 15:26:26 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.8
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 2.5
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 0.5
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.9
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 0.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 4.0
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|